Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 116,654,920
  • Shares Outstanding, K 253,719
  • Annual Sales, $ 11,020 M
  • Annual Income, $ -535,600 K
  • EBIT $ 3,993 M
  • EBITDA $ 4,201 M
  • 60-Month Beta 0.32
  • Price/Sales 10.66
  • Price/Cash Flow N/A
  • Price/Book 6.85

Options Overview Details

View History
  • Implied Volatility 25.18% (+0.77%)
  • Historical Volatility 27.75%
  • IV Percentile 18%
  • IV Rank 12.37%
  • IV High 47.19% on 04/08/25
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 3) 5.95 (1.29%)
  • Put/Call Vol Ratio 1.19
  • Today's Volume 1,549
  • Volume Avg (30-Day) 1,948
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 40,622
  • Open Int (30-Day) 40,842
  • Expected Range 453.83 to 465.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 33 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 4.41
  • Number of Estimates 9
  • High Estimate 4.77
  • Low Estimate 4.00
  • Prior Year 3.54
  • Growth Rate Est. (year over year) +24.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
423.45 +8.58%
on 12/01/25
464.44 -1.00%
on 12/24/25
+26.17 (+6.04%)
since 11/28/25
3-Month
385.86 +19.16%
on 09/30/25
464.44 -1.00%
on 12/24/25
+64.47 (+16.31%)
since 09/29/25
52-Week
362.50 +26.84%
on 08/11/25
519.68 -11.53%
on 03/14/25
+51.02 (+12.48%)
since 12/27/24

Most Recent Stories

More News
2 Nasdaq 100 Stocks Worth Investigating and 1 We Turn Down

2 Nasdaq 100 Stocks Worth Investigating and 1 We Turn Down

TSLA : 459.64 (-3.27%)
VRTX : 459.78 (-0.67%)
EA : 204.27 (-0.25%)
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 44 th Annual J.P. Morgan...

VRTX : 459.78 (-0.67%)
2 Cash-Producing Stocks to Consider Right Now and 1 We Find Risky

2 Cash-Producing Stocks to Consider Right Now and 1 We Find Risky

SPB : 60.31 (+0.42%)
VRTX : 459.78 (-0.67%)
VRT : 165.62 (-1.17%)
2 Reasons to Watch VRTX and 1 to Stay Cautious

2 Reasons to Watch VRTX and 1 to Stay Cautious

VRTX : 459.78 (-0.67%)
1 Large-Cap Stock to Consider Right Now and 2 Facing Challenges

1 Large-Cap Stock to Consider Right Now and 2 Facing Challenges

VRTX : 459.78 (-0.67%)
FDX : 292.89 (-1.16%)
MET : 79.99 (-0.39%)
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in...

VRTX : 459.78 (-0.67%)
Stocks Climb on Fed Rate Cut Optimism

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up by +0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.86%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.20%. December...

MSTR : 155.39 (-2.15%)
AMAT : 263.05 (+0.44%)
GTLB : 38.22 (+1.00%)
ACHC : 14.50 (-1.29%)
DHI : 145.96 (-0.25%)
ADI : 275.63 (-0.44%)
FISV : 67.28 (-0.33%)
GLXY : 23.16 (-1.03%)
BLDR : 103.45 (-0.52%)
TXN : 175.69 (-0.67%)
$IUXX : 25,525.56 (unch)
COIN : 233.77 (-1.32%)
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today

Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today

VRTX : 459.78 (-0.67%)
Stocks Recover on Fed Rate Cut Expectations

The S&P 500 Index ($SPX ) (SPY ) today is up by +0.18%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.06%. December E-mini S&P...

MSTR : 155.39 (-2.15%)
GTLB : 38.22 (+1.00%)
ACHC : 14.50 (-1.29%)
DHI : 145.96 (-0.25%)
FISV : 67.28 (-0.33%)
GLXY : 23.16 (-1.03%)
BLDR : 103.45 (-0.52%)
TXN : 175.69 (-0.67%)
$IUXX : 25,525.56 (unch)
COIN : 233.77 (-1.32%)
ASML : 1,065.99 (-0.63%)
ZNH26 : 112-210 (-0.06%)
Stocks Pressured by Labor Market Weakness and AI-Demand Concerns

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.49%. December E-mini S&P...

MSTR : 155.39 (-2.15%)
GTLB : 38.22 (+1.00%)
ACHC : 14.50 (-1.29%)
DHI : 145.96 (-0.25%)
GLXY : 23.16 (-1.03%)
BLDR : 103.45 (-0.52%)
TXN : 175.69 (-0.67%)
$IUXX : 25,525.56 (unch)
M : 22.10 (-1.65%)
COIN : 233.77 (-1.32%)
ZNH26 : 112-210 (-0.06%)
PHVS : 25.74 (-0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 469.17
2nd Resistance Point 466.36
1st Resistance Point 463.07
Last Price 459.78
1st Support Level 456.97
2nd Support Level 454.16
3rd Support Level 450.87

See More

52-Week High 519.68
Last Price 459.78
Fibonacci 61.8% 459.64
Fibonacci 50% 441.09
Fibonacci 38.2% 422.54
52-Week Low 362.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar